Irritable Bowel Syndrome (IBS) Treatment Market Share, Size, Trends, Industry Analysis Report, By Medical Condition (IBS -Diarrhea, IBS - Constipation, IBS - Mixed) By Drug Type; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032
- Published Date:Jan-2024
- Pages: 117
- Format: PDF
- Report ID: PM1388
- Base Year: 2023
- Historical Data: 2019-2022
Report Outlook
The global irritable bowel syndrome (IBS) treatment market was valued at USD 3.69 billion in 2023 and is expected to grow at a CAGR of 8.4% during the forecast period.
The market is expanding due to increased R&D activities and the rising number of irritable bowel syndrome (IBS) disorders. Additionally, it is anticipated that throughout the forecast period, product innovations will support market expansion. However, the market for treating irritable bowel syndrome (IBS) is constrained by the availability of a small number of products and the ineffectiveness of treatments.
 Treatment Market.png)
Know more about this report: Request for sample pages
Irritable bowel syndrome (IBS) is a common digestive condition that affects the large intestine. Some warning signs and symptoms include abdominal discomfort, bloating, gas, cramps, and diarrhea or constipation. There are several medications that can be used to treat irritable bowel syndrome, including rifaximin, eluxadoline, lubiprostone, and linaclotide.
The main reasons driving the growth of the irritable bowel syndrome treatment market are the rise in the elderly population, the increase in the incidence of gastrointestinal illnesses and disorders such as altered bowel habits and abdominal discomfort, the increase in the level of stress, and an unhealthy diet.
In addition, other factors that contribute to the market's growth include the expansion of the program to raise awareness of the diagnosis, prevention, and management of irritable bowel syndrome, as well as the rise in consumer preference for IBS treatments that enhance therapeutic results.
Moreover, irritable bowel syndrome may have been related to COVID-19 infection, which had a favorable effect on the global market for treatments for the condition. Due to the ongoing COVID-19 epidemic, medical device businesses in North America are having trouble controlling their operations. For instance, research studies published in Wolters Kluwer Health, Inc., the COVID-19 pandemic is linked to increases in psychological distress and gastrointestinal symptoms of people with IBS and comorbid anxiety or/and depression.
 Treatment Market1.png)
For Specific Research Requirements, Request for a Customized Report
Industry Dynamics
Growth Drivers
The introduction of numerous pipeline drugs to treat irritable bowel syndrome is anticipated to be a significant growth driver for the irritable bowel syndrome treatment market during the forecast period. Stress levels associated with changing lifestyles are also expected to rise, as people with IBS have a colon that is sensitive to certain foods and stress.
For instance, The International Foundation for Gastrointestinal Disorders has published statistics that indicate that 5–10% of the global population suffers from IBS. Stress does not induce IBS, according to the same source. However, stress can exacerbate or precipitate the symptoms due to the relationship between the brain and the stomach.
IBS is one of the conditions that can be brought on by several risk factors, including food allergies, gastroenteritis in its early stages, sporadic colon movements, an altered serotonin composition in the colon, and moderate celiac disease. It is anticipated that this will cause IBS to become more common worldwide.
The market for treatments for irritable bowel syndrome is expected to develop over the forecast period due to participants in the market progressively adopting expansion tactics, including acquisition. For instance, In Feb 2019, Bausch Health Companies, Inc. purchased particular assets from Synergy Pharma, a pharmaceutical company, including its pill TRULANCE, which treats people with chronic idiopathic constipation and irritable bowel syndrome.
Report Segmentation
The market is primarily segmented based on medical condition, drug type, distribution channel, and region.
|
By Medical Condition |
By Drug Type |
By Distribution Channel |
By Region |
|
|
|
|
Know more about this report: Request for sample pages
IBS with Diarrhea Segment Accounted for the Largest Market Share
The IBS with diarrhea segment acquired the largest share in 2022. irritable bowel syndrome treatment market share in 2022. During the projected period, this category is also anticipated to develop at the quickest rate due to the rise in gastrointestinal illnesses, including constipation and diarrhea, as a result of changing lifestyles and an increase in the number of older adults and growth in the use of medications such linaclotide and lubiprostone and also greater awareness among patients of the need to treat irritable bowel syndrome.
Furthermore, the incidence of IBS among both men and women is expected to increase in the future years, which is expected to increase demand for medications that can treat both constipation and diarrhea.
 Treatment Market Seg.png)
Rifaximin Segment Held the Highest Market Revenue Share
The rifaximin segment will have the highest revenue and is anticipated to lead over the projection period. The rise in the geriatric population, rising prevalence of irritable bowel syndrome, improved diagnosis, and development of technologically advanced treatment products are all factors that have contributed to the demand for irritable bowel syndrome treatment market products globally.
In addition, the linaclotide drug type segment with the most significant share. The same sector is anticipated to see the greatest CAGR in the market throughout the projected period. The market expansion for the industry is attributable to elements like rising market consolidation for developing and commercializing linaclotide to treat IBS and increasing production of generic versions of linaclotide.
North America Dominated the Global Market in 2022
North America dominated the global industry in 2022 and will likely maintain its dominance over the anticipated period. A high presence of innovative goods, solid healthcare infrastructure, and the existence of significant market participants contributed to the area holding the largest share due to increased awareness of the illness and the presence of substantial competitors in the area, including Ironwood Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., and Abbott.
 Treatment Market Reg.png)
Competitive Insight
Some of the major players operating in the global market include Astellas Pharma Inc;, GlaxoSmithKline Plc, Abbott Laboratories, Takeda Pharmaceutical Company Ltd, Johnson & Johnson, Novartis AG, AstraZeneca plc, Sebela Pharmaceuticals Inc, Synthetic Biologics, Inc, Bausch Health, Synergy Pharmaceuticals Inc.
Recent Developments
- In August 2021, Dr. Reddy's Laboratories Ltd. introduced an adjuvant therapy clidinium bromide capsules USP and chlorodiazepoxide hydrochloride treating peptic ulcer, acute enterocolitis, and irritable bowel syndrome.
- In March 2021, the Nutrition Society of India and Abbott company partnered together to raise awareness about patients suffering from GI disorders. Conditions like chronic pancreatitis, constipation to peptic ulcer, and irritable bowel syndrome.
Irritable Bowel Syndrome (IBS) Treatment Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 3.99 billion |
|
Revenue forecast in 2032 |
USD 7.60 billion |
|
CAGR |
8.4% from 2024 – 2032 |
|
Base year |
2023 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2024 – 2032 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2024 to 2032 |
|
Segments Covered |
By Medical Condition, By Drug Type, By Distribution Channel, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
|
Key Companies |
Astellas Pharma Inc;, GlaxoSmithKline Plc, Abbott Laboratories, Takeda Pharmaceutical Company Ltd, Johnson & Johnson, Novartis AG, AstraZeneca plc, Sebela Pharmaceuticals Inc, Synthetic Biologics, Inc, Bausch Health, Synergy Pharmaceuticals Inc. |
FAQ's
The irritable bowel syndrome (IBS) treatment market report covering key segments are medical condition, drug type, distribution channel, and region.
Irritable Bowel Syndrome (IBS) Treatment Market Size Worth $7.60 billion By 2032 .
The global irritable bowel syndrome (IBS) treatment market expected to grow at a CAGR of 8.4% during the forecast period.
North America is leading the global market.
Irritable bowel syndrome (IBS) treatment market report key driving factors are Increase in geriatric population and Increasing prevalence of IBS.
© 2024 Polaris Market Research and Consulting. All rights reserved
